1[1]Jones CD, Jevnikar MG, Pike AJ, et al. Antiestrogens. Structure-activity studies in a series of 3-Kroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl) benzo [b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]-phenyl]menthanone hydrochloride (LY156758), a remarkablely effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem, 1984, 27:1057
2[2]Thompson EW, Reich R, Shima TB, et al. Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res, 1988, 48:6764
3[3]Anzano MA, Peer CW, Smith JM, et al. Chemprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinic acid. J Nat'l Cancer Inst, 1996, 88(2):123
4[4]Zuckerman SH, Bryan N. Inhibition of LDL oxidationa and myeloperoxidase dependent tyrosl radical formation by the selective estrogen receptor modulator raloxifene (LY 139481 HCL). Atherosclerosis, 1996, 126:65
5[5]Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY 139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest, 1994, 93:63
6[6]Kauffman RF, Bensch WR, Rouderbush RE, et al. Hypocholesterolemic activity of raloxifene (LY 139481): pharmacolo-gical characterization as a selective estrogen receptor modulator. J Pharmacol Exp Ther, 1997, 280:146
7[7]Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA, 1998, 279(18):1445
8[8]Sato M, Kim J, Short LL, et al. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J Pharmacol Exp Ther, 1995, 272(3):1252
9[9]Sato M, Bryant HU, Iversen P, et al. Advantages of raloxifene over alendronate or estrogen on nonreproducitve and reproductive tissues in the long-trem dosing of ovariectomized rats. J Pharmacol Exp Ther, 1996, 279(1):298
10[10]Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Eng J Med, 1997, 337(23):1641
3SCHOEN W R, LADOUCEUR G H, COOK J H, et al. Preparation of substituted biphenyls as glucagons receptor antagonists, US: 6218431[P]. 2001-04-17.
4MASSIMO F, FABRIZIO Z. Process for preparing raloxifene hydrochloride, WO.. 2005003116[P]. 2005- 01-13.
5Jones CD, Jevnikar MG, Pike AJ, et al. Antiestrogens. 2. " Structure-activity studies in a series of 3-aroyl-2-aryib enzo [b] thio phene Derivatives leading to [ 6-hydroxy-2- ( 4-hydroxyphenyl ) benzo [ b ] thien-3-yl ] [ 4- [ 2- ( 1 piperdinyl ) ethoxy ] -phenyl ] met hanone Hydrochloride( LY156758 ), a remarkably effective estrogen antagonist with onlyminimal intrinsic estrogenicity [ J ].J Med Chem, 1984, 27 ( 8 ) :1057- 1066.
6Jones CD. Benzothiophene compounds and process for preparing them[P]. EP,0062503. 1982 - 04 - 01 .
7Jones CD, Jevnikar MG, Pike AJ, et al. Antiestrogens. 2.1 Structure-activitystudies in a series of 3-aroyl-2-aryibenzo[b]thiophene Derivatives leading to[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]-phenyl]methanoneHydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimalintrinsic estrogenicity[J]. J Med Chem, 1984, 27(8):1057.
8U.S. Patent[P].4380635 ,1983-04-19.
9Rossouw JE, Anderson GL, Prentice RL, et al. Risk and benefits of estrogen plus progestin in healty postmenopausal women:principal resulesf rom the women's health initiative randomized controlled trial [ J ]. JAMA ,2002,288(3) :321-333.
10Cummings SR, Echkert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women:results form the MORE randomized trial[J] .JAMA, 1999,281(23) :2189-2197.
